Gedeon Richter and INOVIO expand cooperation in the development of DNA vaccine from COVID-19

Richter-Helm Biologics, a joint venture of Gedeon Richter and Helm AG, established to develop and produce high-quality biotechnology products using microorganisms, announced the signing of a new agreement with us company INOVIO on the large scale production of the experimental DNA vaccine from COVID-19 – INO-4800. Currently, in the US it is already undergoing phase I clinical studies II and phase III evaluation of its effectiveness can be held this summer.

INOVIO and Richter-Helm BioLogics collaborate with 2014. The American company has already started the production of plasmids on the capacity of their partner for their further use in the development of DNA drugs. Apply production technology developed by VGXI Inc. and has proven effective in previous projects.

Company INOVIO was formed a global coalition of scientists, partners and sponsors to expedite the development of vaccines INO-4800.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]